SEER (SEER) Q3 2025: Instrument Shipments Triple, Academic Uptake Surges Despite Funding Headwinds

November 6, 2025 | By EarningsIQ Research

SEER’s Q3 2025 results reveal a business navigating persistent funding and macro pressures, yet delivering record instrument placements and accelerating third-party validation. Strategic partnerships and a surge in academic adoption are building a foundation for future growth, even as government shutdowns and budget uncertainties cloud near-term predictability. Investors should watch for large-scale study wins and Thermo Fisher partnership expansion as critical levers heading into 2026.

Summary

• Academic Adoption Accelerates: Academic and government customers now comprise a higher share of revenue, reflecting broadening platform validation.
• Thermo Fisher Partnership Gains Traction: Joint sales and biobank pipeline signal expanding commercial reach despite macro headwinds.
• Large-Scale Study Momentum Builds: SEER’s technology is powering population-scale research, positioning it for leadership in deep proteomics.

Performance Analysis

SEER reported $4.1 million in Q3 revenue, a modest 2% year-over-year increase, as the company continued to contend with customer capital spending constraints and elongated sales cycles. Instrument shipments were a standout, with nearly three times as many shipped in the first nine months of 2025 as in all of 2024, underscoring growing demand for the ProteoGraph platform. Notably, more than half of these shipments were enabled by the Strategic Instrument Placement (SIP), a program designed to help capital-constrained customers access SEER’s technology through operating budgets rather than upfront purchases.

Gross margin improved to 51%, up from 48% a year ago, driven by a favorable mix of consumables and services. Operating expenses declined 18% year-over-year, reflecting disciplined cost management, particularly in R&D and SG&A. SEER ended the quarter with a robust $251 million in cash, and has repurchased 14% of its shares outstanding since initiating its buyback program, signaling management’s confidence in intrinsic value.

• Instrument Placement Surge: Nearly threefold increase in shipments year-to-date, with two-thirds of Q3 placements to customers previously using SEER’s Technology Access Center (STAC).
• Consumables and Services Drive Margins: Higher mix of recurring revenue streams supported gross margin expansion.
• Cost Discipline Evident: Operating expense reductions outpaced revenue growth, supporting cash burn moderation.

Despite a still-sizeable net loss, SEER’s cash runway remains strong, and management reiterated confidence in reaching cash flow breakeven with current resources.

Executive Commentary

Strategic Positioning

1. Platform Validation and Scientific Momentum

SEER’s ProteoGraph platform is gaining third-party validation, with a record 13 customer publications in Q3 and 66 to date, nearly half published in 2025 alone. These studies, including large-scale genomics and disease biomarker research, are increasingly produced independently by customers, demonstrating growing confidence and adoption. The technology’s ability to detect protein isoforms and link genetic variation to proteomic signatures is differentiating SEER from affinity-based competitors.

2. Commercial Access Expansion

The Strategic Instrument Placement (SIP) and STAC programs are lowering adoption barriers, enabling capital-constrained customers—especially in academia—to access SEER’s technology. The majority of new instrument placements now come from customers who first engaged through STAC, creating a pipeline for future direct sales and consumables revenue.

3. Thermo Fisher Partnership and Biobank Penetration

SEER’s expanded partnership with Thermo Fisher Scientific is beginning to yield results, with the first joint instrument sales and a developing pipeline of large biobank opportunities. This collaboration positions SEER to compete for population-scale studies and further integrate its platform into high-throughput proteomics workflows.

4. Large-Scale Study Enablement

SEER is now powering studies of 10,000 to 20,000 samples, with management predicting the first 100,000-sample mass spec study could arrive in 2026. As biobanks shift from targeted to deep, unbiased proteomics, SEER’s platform is positioned as the gold standard for scalability and biological insight.

5. Capital Allocation and Shareholder Alignment

The company’s aggressive buyback program—repurchasing 14% of shares outstanding— reflects management’s conviction in the long-term opportunity and a belief that the current share price undervalues the business’s progress and prospects.

Key Considerations

Q3 2025 was marked by a clear divergence between persistent macro headwinds and strengthening underlying demand signals. SEER’s ability to grow its installed base and deepen customer engagement, despite funding volatility, highlights both execution discipline and platform stickiness.

Key Considerations:

• Academic and Government Resilience: Despite the government shutdown and grant delays, academic and government customers now represent 40% of year-to-date revenue, up from last year.
• Recurring Revenue Growth: Increased sales of consumables and services are improving margin visibility and reducing reliance on lumpy instrument sales.
• Pipeline for Large Studies: Multiple active discussions with biobanks and research consortia signal potential for step-change in instrument and consumables demand.
• Thermo Fisher Collaboration Scaling: Joint sales and integrated solutions are opening doors to new customer segments and larger research projects.

Risks

Budget constraints, elongated sales cycles, and ongoing government funding uncertainty—especially around NIH grants and the impact of the recent shutdown— remain significant near-term risks. While academic and government engagement is rising, macro headwinds could delay instrument orders and project starts, potentially impacting Q4 shipments and 2026 visibility. Competitive pressure from targeted proteomics platforms and evolving customer procurement models are additional watchpoints.

Forward Outlook

For Q4 2025, SEER guided to:

• Revenue likely in the lower half of the $17 to $18 million full-year range
• Continued pressure from budget constraints and funding uncertainty

For full-year 2025, management maintained guidance:

• $17 to $18 million in revenue (24% growth at midpoint over 2024)

Management highlighted several factors that will shape Q4 and early 2026:

• Potential for delayed shipments if the government shutdown persists
• Ongoing momentum in large-scale study wins and partnership-driven opportunities

Takeaways

SEER’s Q3 results reinforce the platform’s scientific relevance and growing adoption, even as macro and funding headwinds persist. The company’s expanding installed base, deepening academic engagement, and early success with Thermo Fisher position it for inflection if funding visibility improves.

• Installed Base Expansion: Record instrument shipments and recurring revenue growth point to a compounding customer base, setting the stage for future scale.
• Strategic Partnerships Matter: Thermo Fisher collaboration is unlocking new channels and large-scale opportunities, but material revenue contribution will hinge on execution in 2026.
• Watch for Large Study Catalysts: Biobank wins and population-scale projects are likely to be the most significant drivers of upside or downside in coming quarters.

Conclusion

SEER is executing through a challenging funding environment by expanding its installed base, deepening customer validation, and leveraging strategic partnerships. While near-term visibility remains clouded by macro and policy risks, the company’s positioning for large-scale, unbiased proteomics research is strengthening, with multiple levers for future growth.

Industry Read-Through

SEER’s experience in Q3 highlights both the vulnerability and opportunity facing life sciences instrumentation providers as academic and government funding fluctuates. The shift toward population-scale, multi-omic research is accelerating demand for high-throughput, unbiased proteomics, but procurement cycles are increasingly tied to grant and policy cycles. Competitors in proteomics, genomics, and analytical instrumentation should expect similar volatility in academic and biobank segments, with partnerships and flexible access models (like SIP and STAC) becoming critical for customer acquisition and retention. Vendors able to deliver both scientific differentiation and commercial adaptability will be best positioned for the next wave of translational research funding.

SEER Health Care Life Sciences Tools Proteomics Academic Research Biobanks Thermo Fisher Consumables